公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
1998 | Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity | Kuo M.-L.; Shen S.-C.; CHIH-HSIN YANG ; Chuang S.-E.; ANN-LII CHENG ; Huang T.-S. | Oncogene | 39 | 35 | |
2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | JIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
2000 | BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells | CHIH-HSIN YANG ; Schneider E.; Kuo M.-L.; Volk E.L.; Rocchi E.; YAO-CHANG CHEN | Biochemical Pharmacology | 128 | 118 | |
2021 | Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer | Nazha B.; CHIH-HSIN YANG ; Owonikoko T.K. | Future Oncology | 40 | 30 | |
2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Clinical Lung Cancer | 16 | 17 | |
2019 | Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? | CHIH-HSIN YANG | The Lancet Oncology | 3 | 3 | |
2011 | Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) | Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG ; Mok T.S.K. | Journal of Clinical Oncology | 1256 | 1128 | |
2014 | Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) | Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; CHIH-HSIN YANG ; Klughammer B; Colburn D; Miller V; Johnson B.E. | Journal of Thoracic Oncology | 16 | 12 | |
2023 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results | Gutierrez, Martin; Lam, Wei-Sen; Hellmann, Matthew D; Gubens, Matthew A; Aggarwal, Charu; Tan, Daniel Shao Weng; Felip, Enriqueta; Chiu, Joanne W Y; Lee, Jong-Seok; CHIH-HSIN YANG ; Garon, Edward B; Finocchiaro, Giovanna; Ahn, Myung-Ju; Luft, Alexander; Landers, Gregory A; Basso, Andrea; Ma, Hua; Kobie, Julie; Palcza, John; Cristescu, Razvan; Fong, Lawrence; Snyder, Alexandra; Yuan, Jianda; Herbst, Roy S | Nature medicine | 2 | 0 | |
2023 | Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial | CHIH-HSIN YANG ; Liu, Geoffrey; Lu, Shun; He, Jianxing; Burotto, Mauricio; Ahn, Myung-Ju; Kim, Dong-Wan; Liu, XiaoQing; Zhao, Yanqiu; Vincent, Sylvie; Yin, Jiani; Ma, Xin; Lin, Huamao M; Popat, Sanjay | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 4 | 0 | |
2020 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial | Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG ; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. | Journal of Clinical Oncology | 235 | 196 | |
2021 | Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial | Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG ; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. | Journal of Thoracic Oncology | 160 | 119 | |
2018 | Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer | Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG ; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. | New England Journal of Medicine | 661 | 556 | |
2021 | Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3) | Popat S.; Liu G.; Lu S.; Song G.; Ma X.; CHIH-HSIN YANG | Future Oncology | 11 | 6 | |
2024 | Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial | Garon, Edward B; Lu, Shun; Goto, Yasushi; De Marchi, Pedro; Paz-Ares, Luis; Spigel, David R; Thomas, Michael; CHIH-HSIN YANG ; Ardizzoni, Andrea; Barlesi, Fabrice; Orlov, Sergey; Yoshioka, Hiroshige; Mountzios, Giannis; Khanna, Sadhvi; Bossen, Claudia; Carbini, Mariana; Turri, Sabine; Myers, Andrea; Cho, Byoung Chul | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 | | |
2016 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study | Langer C.J; Gadgeel S.M; Borghaei H; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG ; Gubens M; Sequist L.V; Awad M.M; Fiore J; Ge Y; Raftopoulos H; Gandhi L; KEYNOTE-021 investigators | The Lancet Oncology | 1162 | 1066 | |
2008 | Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy | CHAO-CHI HO ; SUNG-HSIN KUO ; PEI-HSIN HUANG ; Huang H.-Y.; CHIH-HSIN YANG ; PAN-CHYR YANG | Lung Cancer | 109 | 98 | |
2021 | CD73 Is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancer | Griesing S.; BIN-CHI LIAO ; CHIH-HSIN YANG | Anticancer Research | 16 | 15 | |
2023 | Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis | Soo, Ross A; Cho, Byoung Chul; Kim, Joo-Hang; Ahn, Myung-Ju; Lee, Ki Hyeong; Zimina, Anastasia; Orlov, Sergey; Bondarenko, Igor; Lee, Yun-Gyoo; Lim, Yueh Ni; Lee, Sung Sook; Lee, Kyung-Hee; Pang, Yong Kek; Fong, Chin Heng; Kang, Jin Hyoung; Lim, Chun Sen; Danchaivijitr, Pongwut; Kilickap, Saadettin; CHIH-HSIN YANG ; Arslan, Cagatay; Lee, Hana; Park, Seong Nam; Cicin, Irfan | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 1 | | |
2023 | Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey | Linardou, H; Adjei, A A; Bajpai, J; Banerjee, S; Berghoff, A S; Mathias, C Cerqueira; Choo, S P; Dent, R; Felip, E; Furness, A J S; Garassino, M C; Garralda, E; Konsoulova-Kirova, A; Letsch, A; Menzies, A M; Mukherji, D; Peters, S; Sessa, C; Tsang, J; CHIH-HSIN YANG ; Garrido, P | ESMO open | 4 | | |